Baidu
map

筹备申报药物临床试验(GCP)机构资格认定的关键环节

2014-03-03 刘敏,樊文竹 华西医学

  我国政府对实施临床试验的医疗机构实行资格准入制度,即临床试验必须在国家食品药品监督管理局 (SFDA)批准的临床试验机构进行。而医疗机构资格认定具有明确程序与标准[1],以保证医疗机构具备一定的条件和资质,降低申报者选择研究机构的盲目 性及受试者参加临床研究的风险[2]。一些实力较强的医疗机构或实力较为雄厚的专业因未申请机构认证而无法参加新药的临床试验,这是一种资源的浪费 [3]。作

  我国政府对实施临床试验的医疗机构实行资格准入制度,即临床试验必须在国家食品药品监督管理局 (SFDA)批准的临床试验机构进行。而医疗机构资格认定具有明确程序与标准[1],以保证医疗机构具备一定的条件和资质,降低申报者选择研究机构的盲目 性及受试者参加临床研究的风险[2]。一些实力较强的医疗机构或实力较为雄厚的专业因未申请机构认证而无法参加新药的临床试验,这是一种资源的浪费 [3]。作为省级肿瘤专科医院,2012年6月,SFDA公告2012年第38号认定我院具有药物临床试验机构资格,认定专业为肿瘤、中医肿瘤、医学影像 (诊断)、医学影像(核医学)、医学影像(治疗)和麻醉。通过筹备申报和接受现场检查,我们深刻体会到药物临床试验组织机构建设、药物临床试验质量管理规范(GCP)培训、材料组织在资格认定中的重要性。本文就我院在筹备申报药物临床试验机构资格认定过程中的经验现总结如下。 1 强有力的组织机构保障 1.1 药物临床试验机构办公室  《药物临床试验机构资格认定办法(试行)》[4]附件2《药物临床试 验机构资格认定标准》中组织管理机构检查分值为100分,其中机构办公室人员资质和能力占3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1688503, encodeId=46d91688503c2, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69964, encryptionId=327b699645c, topicName=申报)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a1628602102, createdName=1508842480_96220446, createdTime=Fri Apr 11 07:56:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294083, encodeId=e2301294083ab, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7885, encryptionId=fd4ae8852b, topicName=GCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480890, encodeId=1f7a1480890a2, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1688503, encodeId=46d91688503c2, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69964, encryptionId=327b699645c, topicName=申报)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a1628602102, createdName=1508842480_96220446, createdTime=Fri Apr 11 07:56:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294083, encodeId=e2301294083ab, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7885, encryptionId=fd4ae8852b, topicName=GCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480890, encodeId=1f7a1480890a2, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=)]
    2014-03-05 zhangfenasdf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1688503, encodeId=46d91688503c2, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69964, encryptionId=327b699645c, topicName=申报)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a1628602102, createdName=1508842480_96220446, createdTime=Fri Apr 11 07:56:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294083, encodeId=e2301294083ab, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7885, encryptionId=fd4ae8852b, topicName=GCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480890, encodeId=1f7a1480890a2, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Wed Mar 05 13:56:00 CST 2014, time=2014-03-05, status=1, ipAttribution=)]

相关资讯

GCP的基本原则(中英文对照)

 1.1        THE BASIC TENETS OF GCP GCP的基本原则 The primary reason for the presence of a GCP code of practice is to protect human rights. If this simple principl

GCP基础指南中英文双语对照

Introduction前言(赵宁翻译 meking第一次校对cassals第2次校对)The overall aim of this work is to provide a reference book which describes the general framework for conducting GCP-compliant clinical research, particular

现行的临床研究实施(GCP)规范 (中英对照)

                  The Current Rules for Conducting Clinical Research  现行的临床研究实施规范     

Baidu
map
Baidu
map
Baidu
map